NYSE:GSK
GlaxoSmithKline PLC
(NYSE:GSK)
43.36
-0.34
(-0.78%)
As of 2022-06-28 Close (EST)
| 52 Week Rng | - |
| Market Cap | - |
| Avg Volume | - |
| 1M Volatility | - |
| Short Ratio | - |
| P/E Ratio (TTM) | - |
| P/E Ratio (Fwd) | - |
| P/B Ratio | - |
| Div & Yield | - |
ACTION
TICKER
SHARES
STATUS
DUKE_SOME_TRUST_CAPITAL • Duke Emerging Market Portfolio Management (Fall 2021) • Oct 2021
The company recently had its Malaria vaccine get recommended for use from the World Health Organization. This is the first vaccine on the market for this disease, so GSK effectively has a monopoly on this market. GSK has pledged to produce at least 15 million doses through 2028, so they will have sales volume for the foreseeable future as well.
ACTION
TICKER
SHARES
STATUS
ACTION
TICKER
SHARES
STATUS
ACTION
TICKER
SHARES
STATUS
ACTION
TICKER
SHARES
STATUS
Investointi_pojat • Aalto Investment Management Game (Fall 2020) • Nov 2020
Weekly rebalancing of our portfolio weights to 100 000 / asset
ACTION
TICKER
SHARES
STATUS
GRQ30 • Aalto Investment Management Game (Fall 2020) • Nov 2020
Passive investment strategy | The Global 100 -list of sustainable stocks | Chosen 30 stocks from 9 individually weighted sectors, equal weights within sectors | Stocks available in NYSE or NASDAQ | Part of the Healthcare sector | The Global 100 rank 79 in year 2020